Comment on

• Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.

  Vlachojannis GJ, Puricel S, Natsuaki M, Morimoto T, Smits PC, Kimura T. Vlachojannis GJ, et al. EuroIntervention. 2017 Mar 20;12(16):1970-1977. doi: 10.4244/EIJ-D-16-00773. EuroIntervention. 2017. PMID: 27802927 Clinical Trial.
• Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.

  Kereiakes DJ, Meredith IT, Masotti M, Carrié D, Moreno R, Erglis A, Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reitman A, Janssens L, Christen T, Dawkins KD, Windecker S. Kereiakes DJ, et al. EuroIntervention. 2017 Mar 20;12(16):1987-1994. doi: 10.4244/EIJ-D-16-00643. EuroIntervention. 2017. PMID: 27840326 Clinical Trial.
• Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients.

  Mennuni MG, Stefanini GG, Pagnotta PA, Pllaha E, Araco M, Meelu OA, Turati F, Reimers B, Sardella G, Presbitero P. Mennuni MG, et al. EuroIntervention. 2017 Mar 20;12(16):1978-1986. doi: 10.4244/EIJ-D-16-00276. EuroIntervention. 2017. PMID: 27993752